Bridgeway Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Bridgeway Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-70,000	Closed	-$484K	–	1519
2015 Q3	$484K	Sell	70,000 -30,000	-30%	-$244K	0.01%	1045
2015 Q2	$886K	Sell	100,000 -50,000	-33%	-$473K	0.02%	842
2015 Q1	$1.48M	Hold	150,000	–	–	0.03%	636
2014 Q4	$1.84M	Hold	150,000	–	–	0.04%	547
2014 Q3	$1.5M	Hold	150,000	–	–	0.04%	595
2014 Q2	$1.14M	Buy	+150,000	New	+$599K	0.03%	719

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bridgeway Capital Management's ACHN Position: Q4 2015 in Review

Bridgeway Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2015, closing a stake of 70,000 shares — an estimated $484K sold.

Bridgeway Capital Management first reported a position in ACHN in Q2 2014 and held it in 6 quarters. The position peaked at $1.84M in Q4 2014. 152 funds tracked by Wall St. Rank hold ACHN as of Q4 2015.

Bridgeway Capital Management reported no remaining Achillion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Bridgeway Capital Management sold 70,000 Achillion Pharmaceuticals shares in Q4 2015, an estimated $484K.
Bridgeway Capital Management first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 6 quarters.
Bridgeway Capital Management's Achillion Pharmaceuticals position peaked at $1.84M in Q4 2014.
152 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2015.

Based on Bridgeway Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.